Leiden, The Netherlands, 10 september 2024
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has appointed experienced life sciences industry executive, Martijn Negen as COO, with immediate effect.
Since September 2023, Martijn has been supporting VarmX as SVP Global Commercial Strategy & Business Development, and is now stepping up to the COO role. He brings over 25 years’ experience in shaping strategy and executing and overseeing commercialization efforts as well as global business development in the pharmaceutical/biotech sector.
Most recently, Martijn was Vice President of Global Commercial Strategy & Business Development at AM-Pharma. leading commercial strategy development and global launch preparations. Prior to that he held leadership positions at Portola Pharmaceuticals, Teva Global Specialty Medicines, Genentech and other large pharmaceutical companies in the US and Europe.
Martijn holds an International MBA from Pepperdine University and TSM Business School, an International MSc. in Medical Biotechnology from De Montfort University, and a degree in Medical Laboratory Technology with a focus on immunology.
Dr. Jan Öhrström, Chairman of VarmX, said:
“Martijn has been invaluable driving force within VarmX in recent months and we are pleased that he will now have a broader responsibility. He brings decades of management and commercialisation experience particularly within urgent hospital care, including at Portola – launching the only apporved medication in our field.
“Martijn’s appointment will further strengthen VarmX’s ability to navigate the exciting and challenging next phase of our growth, as we raise a Series C funding round and drive forward a pivotal Phase 3 trial in an urgent hospital care setting”.
Notes to Editors
About VarmX
VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.
For further information, please contact:
Vigo Consulting (media enquiries)
Rozi Morris
+44 20 7390 0230
VarmX@vigoconsulting.com